drugset / Trial / NCT04609566
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
NaParallel-groupOpen-labelTreatment
Summary
This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer. There will be several different types of cancer studied in the trial. The cancer must have spread to other parts of the body (metastatic). The study will also find out what side effects occur. A side effect is anything the treatment does besides treat cancer. This is a multi-cohort study.
Timeline
- Start
- 2021-01-26
- Primary completion
- 2026-02-03
- Completion
- 2026-02-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brentuximab Vedotin | Monoclonal antibody | 1.8 mg/kg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |